董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Imran Alibhai | 男 | Director and Chief Executive Officer | 50 | 311.61万美元 | 44.12 | 2025-07-08 |
| Wallace Hall | 男 | Independent Director | 64 | 15.55万美元 | 未持股 | 2025-07-08 |
| Michael Stephen Wyzga | 男 | Independent Director | 71 | 17.06万美元 | 未持股 | 2025-07-08 |
| Susan Shiff | 女 | Independent Director | 65 | 26.50万美元 | 1.81 | 2025-07-08 |
| Sujal Shah | 男 | Chairman of the Board | 53 | 18.42万美元 | 2.24 | 2025-07-08 |
| Cynthia Smith | 女 | Independent Director | 57 | 15.52万美元 | 0.40 | 2025-07-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Imran Alibhai | 男 | Director and Chief Executive Officer | 50 | 311.61万美元 | 44.12 | 2025-07-08 |
| Dan Conn | 男 | Chief Financial Officer | 59 | 113.95万美元 | 未持股 | 2025-07-08 |
| John Kauh | 男 | Chief Medical Officer | 53 | 115.67万美元 | 7.75 | 2025-07-08 |
| Stephen O'Brien | -- | Principal Accounting Officer, Vice President, Finance and Corporate Controller | -- | 未披露 | 未持股 | 2025-07-08 |
| Jeffrey Larson | 男 | Senior Vice President, Research and Development | 65 | 未披露 | 未持股 | 2025-07-08 |
| Yixin Joseph Chen | 男 | Vice President, Chemistry, Manufacturing and Controls | 66 | 未披露 | 未持股 | 2025-07-08 |
董事简历
中英对照 | 中文 | 英文- Imran Alibhai
-
合并完成后，Imran Alibhai被任命为首席执行官和董事会成员。Alibhai博士在2018年12月至2025年4月期间担任Legacy Tvardi的首席执行官和董事会成员。自2018年以来，Alibhai博士还担任NASA太空健康转化研究所的科学顾问委员会成员。在担任Legacy Tvardi的首席执行官之前，Alibhai博士是DNATrix的高级副总裁兼董事总经理，DNATrix是一家临床阶段的生物技术公司，在2014年至2018年期间开发用于癌症的溶瘤病毒。2010年至2013年，Alibhai博士是Peter J. Solomon医疗保健咨询集团的投资银行家，专注于以科学为基础的市场的并购交易，包括生物制药、医疗设备/诊断和生命科学工具。2007年至2010年，Alibhai博士在Alexandria Venture Investments担任高级董事，负责对医疗保健领域新兴公司和基金的投资。从2006年到2007年，他指导投资PIPE和MPM Capital的BioEquities对冲基金的多头/空头头寸。Alibhai博士在得克萨斯大学Southstern医学院获得分子神经科学博士学位，在杜克大学获得生物学学士学位。
Imran Alibhai was appointed as Chief Executive Officer and a member of board of directors upon the closing of the Merger. Dr. Alibhai served as Legacy Tvardi's Chief Executive Officer and a member of its board of directors from December 2018 to April 2025. Since 2018, Dr. Alibhai has also served on the Scientific Advisory Board for NASA's Translational Research Institute for Space Health. Prior to serving as Legacy Tvardi's Chief Executive Officer, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotechnology company developing oncolytic vires for cancer from 2014 to 2018. From 2010 to 2013, Dr. Alibhai was an investment banker in Peter J. Solomon's Healthcare Advisory Group, foced on M&A transactions in science based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. From 2007 to 2010, Dr. Alibhai served as the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. From 2006 to 2007, he directed investments for PIPE's and long/short positions in MPM Capital's BioEquities hedge fund. Dr. Alibhai received a Ph.D. in Molecular Neuroscience from the University of Texas Southstern Medical School and a B.S. in Biology from Duke University. - 合并完成后，Imran Alibhai被任命为首席执行官和董事会成员。Alibhai博士在2018年12月至2025年4月期间担任Legacy Tvardi的首席执行官和董事会成员。自2018年以来，Alibhai博士还担任NASA太空健康转化研究所的科学顾问委员会成员。在担任Legacy Tvardi的首席执行官之前，Alibhai博士是DNATrix的高级副总裁兼董事总经理，DNATrix是一家临床阶段的生物技术公司，在2014年至2018年期间开发用于癌症的溶瘤病毒。2010年至2013年，Alibhai博士是Peter J. Solomon医疗保健咨询集团的投资银行家，专注于以科学为基础的市场的并购交易，包括生物制药、医疗设备/诊断和生命科学工具。2007年至2010年，Alibhai博士在Alexandria Venture Investments担任高级董事，负责对医疗保健领域新兴公司和基金的投资。从2006年到2007年，他指导投资PIPE和MPM Capital的BioEquities对冲基金的多头/空头头寸。Alibhai博士在得克萨斯大学Southstern医学院获得分子神经科学博士学位，在杜克大学获得生物学学士学位。
- Imran Alibhai was appointed as Chief Executive Officer and a member of board of directors upon the closing of the Merger. Dr. Alibhai served as Legacy Tvardi's Chief Executive Officer and a member of its board of directors from December 2018 to April 2025. Since 2018, Dr. Alibhai has also served on the Scientific Advisory Board for NASA's Translational Research Institute for Space Health. Prior to serving as Legacy Tvardi's Chief Executive Officer, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotechnology company developing oncolytic vires for cancer from 2014 to 2018. From 2010 to 2013, Dr. Alibhai was an investment banker in Peter J. Solomon's Healthcare Advisory Group, foced on M&A transactions in science based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. From 2007 to 2010, Dr. Alibhai served as the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. From 2006 to 2007, he directed investments for PIPE's and long/short positions in MPM Capital's BioEquities hedge fund. Dr. Alibhai received a Ph.D. in Molecular Neuroscience from the University of Texas Southstern Medical School and a B.S. in Biology from Duke University.
- Wallace Hall
-
华莱士·霍尔在合并完成后被任命为董事会成员。Hall Previoly先生于2018年6月至2025年4月期间担任Legacy Tvardi董事会成员。Hall先生与他人共同创立了tland Partners，LP并担任其总裁，该公司从1999年2月至今主要从事tland缓解银行业务和石油和天然气投资。Hall先生还共同创立了BioMatrix Partners，这是一家专注于公共和私营生物技术公司的投资合伙企业，他从2013年10月至今担任该公司的有限合伙人。从2011年2月到2017年2月，霍尔先生在得克萨斯大学系统董事会任职。霍尔还担任私营公司Vooks，Inc.的董事。霍尔先生获得了得克萨斯大学阿廷分校的经济学学士学位。
Wallace Hall was appointed to board of directors upon the closing of the Merger. Mr. Hall previoly served as a member of Legacy Tvardi's board of directors from June 2018 to April 2025. Mr. Hall cofounded and has served as the President of tland Partners, LP, which is primarily engaged in tland mitigation banking and oil & gas investment from February 1999 to present. Mr. Hall also co founded BioMatrix Partners, an investment partnership foced on public and private biotechnology companies, where he has served as Limited Partner from October 2013 to present. From February 2011 to February 2017, Mr. Hall served on the University of Texas System Board of Regents. Mr. Hall also serves as a director at Vooks, Inc., a private company. Mr. Hall received a B.A. in Economics from the University of Texas at Atin. - 华莱士·霍尔在合并完成后被任命为董事会成员。Hall Previoly先生于2018年6月至2025年4月期间担任Legacy Tvardi董事会成员。Hall先生与他人共同创立了tland Partners，LP并担任其总裁，该公司从1999年2月至今主要从事tland缓解银行业务和石油和天然气投资。Hall先生还共同创立了BioMatrix Partners，这是一家专注于公共和私营生物技术公司的投资合伙企业，他从2013年10月至今担任该公司的有限合伙人。从2011年2月到2017年2月，霍尔先生在得克萨斯大学系统董事会任职。霍尔还担任私营公司Vooks，Inc.的董事。霍尔先生获得了得克萨斯大学阿廷分校的经济学学士学位。
- Wallace Hall was appointed to board of directors upon the closing of the Merger. Mr. Hall previoly served as a member of Legacy Tvardi's board of directors from June 2018 to April 2025. Mr. Hall cofounded and has served as the President of tland Partners, LP, which is primarily engaged in tland mitigation banking and oil & gas investment from February 1999 to present. Mr. Hall also co founded BioMatrix Partners, an investment partnership foced on public and private biotechnology companies, where he has served as Limited Partner from October 2013 to present. From February 2011 to February 2017, Mr. Hall served on the University of Texas System Board of Regents. Mr. Hall also serves as a director at Vooks, Inc., a private company. Mr. Hall received a B.A. in Economics from the University of Texas at Atin.
- Michael Stephen Wyzga
-
合并完成后，Michael Stephen Wyzga被任命为董事会成员。Wyzga Previoly先生于2021年3月至2025年4月期间担任Legacy Tvardi的董事会成员。自2013年11月起，Wyzga先生担任MSW Consulting Inc.的总裁，该公司是一家专注于生命科学领域的战略咨询集团。从2011年12月至2013年11月，Wyzga先生担任Radi Health，Inc.（一家上市生物制药公司）的总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。Wyzga先生还自2018年7月起担任上市公司X4 Pharmaceuticals, Inc.的董事会主席、自2015年7月起担任泛欧交易所交易的生物制药公司GenSight Biologics S.A.的董事会主席以及Mereo BioPharma Group PLC（前身为Oncomed Pharmaceuticals, Inc.）的董事会主席，并于2019年4月通过BINCE组合自2013年10月起担任该公司的董事会主席。他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
Michael Stephen Wyzga was appointed to board of directors upon the closing of the Merger. Mr. Wyzga previoly served on Legacy Tvardi's board of directors from March 2021 to April 2025. Since November 2013, Mr. Wyzga has served as the President of MSW Consulting Inc., a strategic consulting group foced in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radi Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in vario senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is also the Chairman of the board of directors of X4 Pharmaceuticals, Inc., a public company since July 2018, Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company, where he has served since July 2015, and Chairman of the board of directors of Mereo BioPharma Group plc (formerly Oncomed Pharmaceuticals, Inc.), where he served from October 2013 through the biness combination in April 2019. He received an M.B.A. from Providence College and a B.S. from Suffolk University. - 合并完成后，Michael Stephen Wyzga被任命为董事会成员。Wyzga Previoly先生于2021年3月至2025年4月期间担任Legacy Tvardi的董事会成员。自2013年11月起，Wyzga先生担任MSW Consulting Inc.的总裁，该公司是一家专注于生命科学领域的战略咨询集团。从2011年12月至2013年11月，Wyzga先生担任Radi Health，Inc.（一家上市生物制药公司）的总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。Wyzga先生还自2018年7月起担任上市公司X4 Pharmaceuticals, Inc.的董事会主席、自2015年7月起担任泛欧交易所交易的生物制药公司GenSight Biologics S.A.的董事会主席以及Mereo BioPharma Group PLC（前身为Oncomed Pharmaceuticals, Inc.）的董事会主席，并于2019年4月通过BINCE组合自2013年10月起担任该公司的董事会主席。他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
- Michael Stephen Wyzga was appointed to board of directors upon the closing of the Merger. Mr. Wyzga previoly served on Legacy Tvardi's board of directors from March 2021 to April 2025. Since November 2013, Mr. Wyzga has served as the President of MSW Consulting Inc., a strategic consulting group foced in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radi Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in vario senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is also the Chairman of the board of directors of X4 Pharmaceuticals, Inc., a public company since July 2018, Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company, where he has served since July 2015, and Chairman of the board of directors of Mereo BioPharma Group plc (formerly Oncomed Pharmaceuticals, Inc.), where he served from October 2013 through the biness combination in April 2019. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
- Susan Shiff
-
合并完成后，San Shiff作为Cara的指定人员继续留在董事会，并自2020年6月起担任Cara董事会成员。Shiff博士担任Huma.ai的首席执行官，Huma.ai是一家私人控股的健康技术公司，她自2024年7月以来一直担任该职位。从2023年7月到2024年7月，Shiff博士通过她的biness San Shiff Consulting，LLC为生命科学公司提供咨询服务。Previoly，她于2021年3月至2023年7月担任Ontada LLC的总裁兼首席执行官，该公司是一家提供技术、真实世界数据和洞察力以及教育公司。2014年6月至2021年3月，她在默沙东公司担任高级副总裁，并担任观察和真实世界证据中心的负责人，该中心是领导全球药物和疫苗价值的测量和交流的组织。她拥有康奈尔大学的工商管理硕士学位和加州大学洛杉矶分校的博士学位。
Susan Shiff remained on board of directors as a designee of Cara upon the closing of the Merger and served as a member of Cara's board of directors since June 2020. Dr. Shiff serves as Chief Executive Officer of Huma.ai, a privately held health technology company, a position she has held since July 2024. From July 2023 to July 2024, Dr. Shiff provided consulting services to life sciences companies through her biness San Shiff Consulting, LLC. Previoly, she served as President and Chief Executive Officer from March 2021 to July 2023 of Ontada LLC, a provider technology, real world data and insights, and education company. From June 2014 to March 2021, she was a Senior Vice President at Merck & Co and Head of the Center for Observational and Real World Evidence, an organization that lead the measurement and communication of the value of medicines and vaccines worldwide. She holds an M.B.A. from Cornell University and a Ph.D. from the University of California at Los Angeles. - 合并完成后，San Shiff作为Cara的指定人员继续留在董事会，并自2020年6月起担任Cara董事会成员。Shiff博士担任Huma.ai的首席执行官，Huma.ai是一家私人控股的健康技术公司，她自2024年7月以来一直担任该职位。从2023年7月到2024年7月，Shiff博士通过她的biness San Shiff Consulting，LLC为生命科学公司提供咨询服务。Previoly，她于2021年3月至2023年7月担任Ontada LLC的总裁兼首席执行官，该公司是一家提供技术、真实世界数据和洞察力以及教育公司。2014年6月至2021年3月，她在默沙东公司担任高级副总裁，并担任观察和真实世界证据中心的负责人，该中心是领导全球药物和疫苗价值的测量和交流的组织。她拥有康奈尔大学的工商管理硕士学位和加州大学洛杉矶分校的博士学位。
- Susan Shiff remained on board of directors as a designee of Cara upon the closing of the Merger and served as a member of Cara's board of directors since June 2020. Dr. Shiff serves as Chief Executive Officer of Huma.ai, a privately held health technology company, a position she has held since July 2024. From July 2023 to July 2024, Dr. Shiff provided consulting services to life sciences companies through her biness San Shiff Consulting, LLC. Previoly, she served as President and Chief Executive Officer from March 2021 to July 2023 of Ontada LLC, a provider technology, real world data and insights, and education company. From June 2014 to March 2021, she was a Senior Vice President at Merck & Co and Head of the Center for Observational and Real World Evidence, an organization that lead the measurement and communication of the value of medicines and vaccines worldwide. She holds an M.B.A. from Cornell University and a Ph.D. from the University of California at Los Angeles.
- Sujal Shah
-
Sujal Shah，是一位成就卓著的生物制药高管，拥有丰富的领导能力和产品开发经验，以及资本形成方面的业绩记录，这与Opthea董事会在视网膜疾病，尤其是湿性AMD方面的深厚专业知识相辅相成。最近，Shah先生担任CymaBay Therapeutics的总裁兼首席执行官，该公司于2024年3月被吉利德科学以总股权价值约43亿美元收购。
Sujal Shah is an accomplished biopharmaceutical executive with extensive leadership and product development experience and a track record in capital formation that complements the deep expertise in retinal disease, especially wet AMD, of the Opthea Board. Most recently, Mr. Shah served as President and Chief Executive Officer of CymaBay Therapeutics which was acquired by Gilead Sciences for approximately $4.3 billion in total equity value in March 2024. - Sujal Shah，是一位成就卓著的生物制药高管，拥有丰富的领导能力和产品开发经验，以及资本形成方面的业绩记录，这与Opthea董事会在视网膜疾病，尤其是湿性AMD方面的深厚专业知识相辅相成。最近，Shah先生担任CymaBay Therapeutics的总裁兼首席执行官，该公司于2024年3月被吉利德科学以总股权价值约43亿美元收购。
- Sujal Shah is an accomplished biopharmaceutical executive with extensive leadership and product development experience and a track record in capital formation that complements the deep expertise in retinal disease, especially wet AMD, of the Opthea Board. Most recently, Mr. Shah served as President and Chief Executive Officer of CymaBay Therapeutics which was acquired by Gilead Sciences for approximately $4.3 billion in total equity value in March 2024.
- Cynthia Smith
-
Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
Cynthia Smith,served as Chief Commercial Officer of ZS Pharma, Inc., from June 2013 to December 2016. In December 2015, ZS Pharma, Inc. was acquired and became a subsidiary of AstraZeneca. Prior to joining ZS Pharma, Inc., from October 2008 to March 2013, Ms. Smith served as Vice President, Market Access & Commercial Development at Affymax, Inc., a biotechnology company focused on the development and commercialization of novel renal therapies, including a new anemia drug for chronic kidney disease patients. Prior to Affymax, from 2000 to 2008, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before joining the pharmaceutical industry, Ms. Smith served in the White House Office of Management and Budget (OMB) in the Clinton Administration. Ms. Smith serves on the board of directors of Agios Pharmaceuticals, Akebia Therapeutics, Protara Therapeutics, Inc. and Tvardi Therapeutics, Inc. Ms. Smith earned an M.B.A. from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University, and a B.A. from the University of North Carolina at Chapel Hill. - Cynthia Smith是理学硕士和工商管理硕士，自2013年6月以来担任Spero Therapeutics, Inc.的首席商务官。从2008年10月到2013年3月她在Affymax Inc.（关注新肾疗法的开发和商业化的生物技术公司）工作，最近是市场准入和商业发展（Market Access and Commercial Development）的副总裁。从2000年7月到2008年10月她在Merck and Co., Inc.工作，在那里她担任各种管理市场、公司战略和公共事务的领导职位，最近担任医疗体系和医疗战略（Healthcare System and Medicare Strategy）的执行董事。从1995年6月到2000年7月她在克林顿政府下的白宫行政管理和预算局工作。她从北卡罗莱纳大学教堂山分校获得学士学位，从罗格斯大学伊格尔顿研究所获得公共政策硕士学位，从宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。
- Cynthia Smith,served as Chief Commercial Officer of ZS Pharma, Inc., from June 2013 to December 2016. In December 2015, ZS Pharma, Inc. was acquired and became a subsidiary of AstraZeneca. Prior to joining ZS Pharma, Inc., from October 2008 to March 2013, Ms. Smith served as Vice President, Market Access & Commercial Development at Affymax, Inc., a biotechnology company focused on the development and commercialization of novel renal therapies, including a new anemia drug for chronic kidney disease patients. Prior to Affymax, from 2000 to 2008, she held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co. Before joining the pharmaceutical industry, Ms. Smith served in the White House Office of Management and Budget (OMB) in the Clinton Administration. Ms. Smith serves on the board of directors of Agios Pharmaceuticals, Akebia Therapeutics, Protara Therapeutics, Inc. and Tvardi Therapeutics, Inc. Ms. Smith earned an M.B.A. from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University, and a B.A. from the University of North Carolina at Chapel Hill.
高管简历
中英对照 | 中文 | 英文- Imran Alibhai
合并完成后，Imran Alibhai被任命为首席执行官和董事会成员。Alibhai博士在2018年12月至2025年4月期间担任Legacy Tvardi的首席执行官和董事会成员。自2018年以来，Alibhai博士还担任NASA太空健康转化研究所的科学顾问委员会成员。在担任Legacy Tvardi的首席执行官之前，Alibhai博士是DNATrix的高级副总裁兼董事总经理，DNATrix是一家临床阶段的生物技术公司，在2014年至2018年期间开发用于癌症的溶瘤病毒。2010年至2013年，Alibhai博士是Peter J. Solomon医疗保健咨询集团的投资银行家，专注于以科学为基础的市场的并购交易，包括生物制药、医疗设备/诊断和生命科学工具。2007年至2010年，Alibhai博士在Alexandria Venture Investments担任高级董事，负责对医疗保健领域新兴公司和基金的投资。从2006年到2007年，他指导投资PIPE和MPM Capital的BioEquities对冲基金的多头/空头头寸。Alibhai博士在得克萨斯大学Southstern医学院获得分子神经科学博士学位，在杜克大学获得生物学学士学位。
Imran Alibhai was appointed as Chief Executive Officer and a member of board of directors upon the closing of the Merger. Dr. Alibhai served as Legacy Tvardi's Chief Executive Officer and a member of its board of directors from December 2018 to April 2025. Since 2018, Dr. Alibhai has also served on the Scientific Advisory Board for NASA's Translational Research Institute for Space Health. Prior to serving as Legacy Tvardi's Chief Executive Officer, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotechnology company developing oncolytic vires for cancer from 2014 to 2018. From 2010 to 2013, Dr. Alibhai was an investment banker in Peter J. Solomon's Healthcare Advisory Group, foced on M&A transactions in science based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. From 2007 to 2010, Dr. Alibhai served as the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. From 2006 to 2007, he directed investments for PIPE's and long/short positions in MPM Capital's BioEquities hedge fund. Dr. Alibhai received a Ph.D. in Molecular Neuroscience from the University of Texas Southstern Medical School and a B.S. in Biology from Duke University.- 合并完成后，Imran Alibhai被任命为首席执行官和董事会成员。Alibhai博士在2018年12月至2025年4月期间担任Legacy Tvardi的首席执行官和董事会成员。自2018年以来，Alibhai博士还担任NASA太空健康转化研究所的科学顾问委员会成员。在担任Legacy Tvardi的首席执行官之前，Alibhai博士是DNATrix的高级副总裁兼董事总经理，DNATrix是一家临床阶段的生物技术公司，在2014年至2018年期间开发用于癌症的溶瘤病毒。2010年至2013年，Alibhai博士是Peter J. Solomon医疗保健咨询集团的投资银行家，专注于以科学为基础的市场的并购交易，包括生物制药、医疗设备/诊断和生命科学工具。2007年至2010年，Alibhai博士在Alexandria Venture Investments担任高级董事，负责对医疗保健领域新兴公司和基金的投资。从2006年到2007年，他指导投资PIPE和MPM Capital的BioEquities对冲基金的多头/空头头寸。Alibhai博士在得克萨斯大学Southstern医学院获得分子神经科学博士学位，在杜克大学获得生物学学士学位。
- Imran Alibhai was appointed as Chief Executive Officer and a member of board of directors upon the closing of the Merger. Dr. Alibhai served as Legacy Tvardi's Chief Executive Officer and a member of its board of directors from December 2018 to April 2025. Since 2018, Dr. Alibhai has also served on the Scientific Advisory Board for NASA's Translational Research Institute for Space Health. Prior to serving as Legacy Tvardi's Chief Executive Officer, Dr. Alibhai was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotechnology company developing oncolytic vires for cancer from 2014 to 2018. From 2010 to 2013, Dr. Alibhai was an investment banker in Peter J. Solomon's Healthcare Advisory Group, foced on M&A transactions in science based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. From 2007 to 2010, Dr. Alibhai served as the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. From 2006 to 2007, he directed investments for PIPE's and long/short positions in MPM Capital's BioEquities hedge fund. Dr. Alibhai received a Ph.D. in Molecular Neuroscience from the University of Texas Southstern Medical School and a B.S. in Biology from Duke University.
- Dan Conn
并购交易完成后，Dan Conn被任命为首席财务官。Conn先生于2022年1月至2025年4月期间担任Legacy Tvardi的首席财务官。Previoly，Mr. Conn曾在佳士得国际房地产公司担任多个职位，包括2014年1月至2014年10月的首席运营官以及2014年10月至2021年11月的首席执行官和董事会成员。在这些职位上，康恩管理着佳士得的全球房地产品牌授权和经纪业务，并专注于将业务扩展到新的领域和战略发展。2012年1月至2014年1月，Conn先生在布鲁克菲尔德资产管理担任资产管理高级副总裁。在此之前，他于2010年6月至2012年3月在Peter J. Solomon公司重组咨询小组担任董事。在此之前，他曾于2006年10月至2010年6月在D.E. Shaw & Co.，L.P.担任副总裁–中间市场投资和投资组合管理。Connn先生的职业生涯始于并购和证券律师，之后在摩根士丹利从事投资银行业务，随后过渡到该公司的房地产私募股权基金部门。Conn先生获得了加州大学洛杉矶分校安德森BINCE学院的工商管理硕士学位，以及多伦多大学的哲学法学博士和学士学位。
Dan Conn was appointed as Chief Financial Officer upon the closing of the Merger. Mr. Conn served as Legacy Tvardi's Chief Financial Officer from January 2022 to April 2025. Previoly, Mr. Conn held multiple positions at Christie's International Real Estate, including Chief Operating Officer from January 2014 to October 2014 and Chief Executive Officer and a member of the board of directors from October 2014 to November 2021. In these roles, Mr. Conn managed Christie's global real estate brand licensing and brokerage biness and foced on expanding the biness into new areas and strategic development. From January 2012 to January 2014, Mr. Conn served as Senior Vice President of Asset Management at Brookfield Asset Management. Prior to that, he served as a Director in the Restructuring Advisory Group of Peter J. Solomon Company from June 2010 to March 2012. Prior to that, he served as Vice President – Middle Market Investing and Portfolio Management at D.E. Shaw & Co., L.P. from October 2006 to June 2010. Mr. Conn began his career as a mergers and acquisition and securities lawyer before moving into investment banking at Morgan Stanley where he then transitioned into its real estate private equity funds arm. Mr. Conn received an M.B.A. from the Anderson School of Biness at the University of California, Los Angeles and a J.D. and B.A. in Philosophy from the University of Toronto.- 并购交易完成后，Dan Conn被任命为首席财务官。Conn先生于2022年1月至2025年4月期间担任Legacy Tvardi的首席财务官。Previoly，Mr. Conn曾在佳士得国际房地产公司担任多个职位，包括2014年1月至2014年10月的首席运营官以及2014年10月至2021年11月的首席执行官和董事会成员。在这些职位上，康恩管理着佳士得的全球房地产品牌授权和经纪业务，并专注于将业务扩展到新的领域和战略发展。2012年1月至2014年1月，Conn先生在布鲁克菲尔德资产管理担任资产管理高级副总裁。在此之前，他于2010年6月至2012年3月在Peter J. Solomon公司重组咨询小组担任董事。在此之前，他曾于2006年10月至2010年6月在D.E. Shaw & Co.，L.P.担任副总裁–中间市场投资和投资组合管理。Connn先生的职业生涯始于并购和证券律师，之后在摩根士丹利从事投资银行业务，随后过渡到该公司的房地产私募股权基金部门。Conn先生获得了加州大学洛杉矶分校安德森BINCE学院的工商管理硕士学位，以及多伦多大学的哲学法学博士和学士学位。
- Dan Conn was appointed as Chief Financial Officer upon the closing of the Merger. Mr. Conn served as Legacy Tvardi's Chief Financial Officer from January 2022 to April 2025. Previoly, Mr. Conn held multiple positions at Christie's International Real Estate, including Chief Operating Officer from January 2014 to October 2014 and Chief Executive Officer and a member of the board of directors from October 2014 to November 2021. In these roles, Mr. Conn managed Christie's global real estate brand licensing and brokerage biness and foced on expanding the biness into new areas and strategic development. From January 2012 to January 2014, Mr. Conn served as Senior Vice President of Asset Management at Brookfield Asset Management. Prior to that, he served as a Director in the Restructuring Advisory Group of Peter J. Solomon Company from June 2010 to March 2012. Prior to that, he served as Vice President – Middle Market Investing and Portfolio Management at D.E. Shaw & Co., L.P. from October 2006 to June 2010. Mr. Conn began his career as a mergers and acquisition and securities lawyer before moving into investment banking at Morgan Stanley where he then transitioned into its real estate private equity funds arm. Mr. Conn received an M.B.A. from the Anderson School of Biness at the University of California, Los Angeles and a J.D. and B.A. in Philosophy from the University of Toronto.
- John Kauh
合并完成后，John Kauh被任命为首席医疗官。Kauh博士在2023年1月至2025年4月期间担任Legacy Tvardi的首席医疗官。在此之前，Kauh博士曾在HUTCHMED担任多个职位，包括在2020年9月至2023年2月期间担任临床开发副总裁，并在2018年9月至2020年9月期间担任临床开发执行总监。在担任这些职务期间，他负责监督从1期到3期药物的临床开发，并为评估肿瘤学小分子抑制剂的vario全球临床试验提供医疗监督，并亲自领导了索凡替尼的NDA和MAA监管提交。2017年5月至2018年9月，Kauh博士担任Glenmark Pharmaceuticals的临床科学—肿瘤学执行总监。2013年11月至2017年5月，在礼来公司全资子公司ImClone Systems担任高级医疗总监。Kauh博士获得了金梅尔医学院（前称杰斐逊医学院）的医学博士学位和宾夕法尼亚州立大学的科学学士学位。
John Kauh was appointed as Chief Medical Officer upon the closing of the Merger. Dr. Kauh served as Legacy Tvardi's Chief Medical Officer from January 2023 to April 2025. Prior to that, Dr. Kauh held multiple positions at HUTCHMED, including serving as Vice President of Clinical Development from September 2020 to February 2023 and Executive Director, Clinical Development from September 2018 to September 2020. In these roles, he oversaw clinical development of agents ranging from Phase 1 to Phase 3 and provided medical oversight to vario global clinical trials evaluating small molecule inhibitors in oncology and personally led the NDA and MAA regulatory submissions for surufatinib. From May 2017 to September 2018, Dr. Kauh served as the Executive Director of Clinical Science — Oncology at Glenmark Pharmaceuticals. From November 2013 to May 2017, he served as the Senior Medical Director at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. Dr. Kauh received an M.D. from Kimmel College of Medicine (formerly known as Jefferson Medical College) and a B.S. in Science from Penn State University.- 合并完成后，John Kauh被任命为首席医疗官。Kauh博士在2023年1月至2025年4月期间担任Legacy Tvardi的首席医疗官。在此之前，Kauh博士曾在HUTCHMED担任多个职位，包括在2020年9月至2023年2月期间担任临床开发副总裁，并在2018年9月至2020年9月期间担任临床开发执行总监。在担任这些职务期间，他负责监督从1期到3期药物的临床开发，并为评估肿瘤学小分子抑制剂的vario全球临床试验提供医疗监督，并亲自领导了索凡替尼的NDA和MAA监管提交。2017年5月至2018年9月，Kauh博士担任Glenmark Pharmaceuticals的临床科学—肿瘤学执行总监。2013年11月至2017年5月，在礼来公司全资子公司ImClone Systems担任高级医疗总监。Kauh博士获得了金梅尔医学院（前称杰斐逊医学院）的医学博士学位和宾夕法尼亚州立大学的科学学士学位。
- John Kauh was appointed as Chief Medical Officer upon the closing of the Merger. Dr. Kauh served as Legacy Tvardi's Chief Medical Officer from January 2023 to April 2025. Prior to that, Dr. Kauh held multiple positions at HUTCHMED, including serving as Vice President of Clinical Development from September 2020 to February 2023 and Executive Director, Clinical Development from September 2018 to September 2020. In these roles, he oversaw clinical development of agents ranging from Phase 1 to Phase 3 and provided medical oversight to vario global clinical trials evaluating small molecule inhibitors in oncology and personally led the NDA and MAA regulatory submissions for surufatinib. From May 2017 to September 2018, Dr. Kauh served as the Executive Director of Clinical Science — Oncology at Glenmark Pharmaceuticals. From November 2013 to May 2017, he served as the Senior Medical Director at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. Dr. Kauh received an M.D. from Kimmel College of Medicine (formerly known as Jefferson Medical College) and a B.S. in Science from Penn State University.
- Stephen O'Brien
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey Larson
合并完成后，Jeffrey Larson被任命为研发高级副总裁。Larson博士于2020年11月至2025年4月担任Legacy Tvardi的研发高级副总裁。自2016年11月起，他还担任霍顿卫理公会学术研究所、转化研究倡议外部顾问委员会的成员。2018年6月至2020年11月，Larson博士在Iterion Therapeutics担任产品开发副总裁，负责监督化学制造和控制、监管事务以及质量和非临床研发。2015年12月至2018年6月，Larson博士在Beta Cat Pharmaceutical（现为Iterion Therapeutics）担任非临床开发副总裁。2015年12月至2019年2月，Larson博士还在Salari Pharmaceuticals担任非临床开发副总裁。Larson博士在华盛顿州立大学获得毒理学/药理学博士学位，在迈诺特州立大学获得环境科学学士学位。
Jeffrey Larson was appointed as Senior Vice President, Research & Development upon the closing of the Merger. Dr. Larson served as Legacy Tvardi's Senior Vice President, Research & Development, from November 2020 to April 2025. Since November 2016, he has also served a member of the Hoton Methodist Academic Institute, Translational Research Initiative External Advisory Board. From June 2018 to November 2020, Dr. Larson served as Vice President of Product Development at Iterion Therapeutics, where he oversaw chemistry manufacturing and controls, regulatory affairs, and quality and nonclinical research and development. From December 2015 to June 2018, Dr. Larson served as Vice President, Nonclinical Development at Beta Cat Pharmaceutical, which is now Iterion Therapeutics. From December 2015 to February 2019, Dr. Larson also served as Vice President, Nonclinical Development at Salari Pharmaceuticals. Dr. Larson received a Ph.D. in Toxicology/Pharmacology from Washington State University and a B.A. in Environmental Science from Minot State University.- 合并完成后，Jeffrey Larson被任命为研发高级副总裁。Larson博士于2020年11月至2025年4月担任Legacy Tvardi的研发高级副总裁。自2016年11月起，他还担任霍顿卫理公会学术研究所、转化研究倡议外部顾问委员会的成员。2018年6月至2020年11月，Larson博士在Iterion Therapeutics担任产品开发副总裁，负责监督化学制造和控制、监管事务以及质量和非临床研发。2015年12月至2018年6月，Larson博士在Beta Cat Pharmaceutical（现为Iterion Therapeutics）担任非临床开发副总裁。2015年12月至2019年2月，Larson博士还在Salari Pharmaceuticals担任非临床开发副总裁。Larson博士在华盛顿州立大学获得毒理学/药理学博士学位，在迈诺特州立大学获得环境科学学士学位。
- Jeffrey Larson was appointed as Senior Vice President, Research & Development upon the closing of the Merger. Dr. Larson served as Legacy Tvardi's Senior Vice President, Research & Development, from November 2020 to April 2025. Since November 2016, he has also served a member of the Hoton Methodist Academic Institute, Translational Research Initiative External Advisory Board. From June 2018 to November 2020, Dr. Larson served as Vice President of Product Development at Iterion Therapeutics, where he oversaw chemistry manufacturing and controls, regulatory affairs, and quality and nonclinical research and development. From December 2015 to June 2018, Dr. Larson served as Vice President, Nonclinical Development at Beta Cat Pharmaceutical, which is now Iterion Therapeutics. From December 2015 to February 2019, Dr. Larson also served as Vice President, Nonclinical Development at Salari Pharmaceuticals. Dr. Larson received a Ph.D. in Toxicology/Pharmacology from Washington State University and a B.A. in Environmental Science from Minot State University.
- Yixin Joseph Chen
合并完成后，易鑫陈一舟被任命为副总裁，负责化学、制造和控制。陈博士于2021年10月至2025年4月担任Legacy Tvardi的化学、制造和控制副总裁。2015年3月至2021年10月，陈博士担任咨询公司Cheminopti LLC的所有者和总裁，为CMC发展的各个方面提供战略指导和技术领导。从2019年9月到2021年10月，陈博士在商业阶段制药公司SIGA技术公司担任药物开发和制造总监，负责监督美国和欧盟早期开发和商业化的药物物质和药物产品CMC活动。陈博士获得美国田纳西州孟菲斯大学分析化学博士学位和中国天津大学化学工程学士和硕士学位。
Yixin Joseph Chen was appointed as Vice President, Chemistry, Manufacturing and Controls upon the closing of the Merger. Dr. Chen served as Legacy Tvardi's Vice President, Chemistry, Manufacturing and Controls, from October 2021 to April 2025. From March 2015 to October 2021, Dr. Chen served as the Owner and President of Cheminopti LLC, a consulting firm, where he provided strategic guidance and technical leadership for all aspects of CMC development. From September 2019 to October 2021, Dr. Chen served as the Director of Pharmaceutical Development and Manufacturing at SIGA Technology, Inc., a commercial stage pharmaceutical company, where he oversaw both drug substance and drug product CMC activities for early stage development and commercialization in the United States and European Union. Dr. Chen received a Ph.D. in analytical chemistry from the University of Memphis, Tennessee and B.S. and M.S degrees in Chemical Engineering from Tianjin University, China.- 合并完成后，易鑫陈一舟被任命为副总裁，负责化学、制造和控制。陈博士于2021年10月至2025年4月担任Legacy Tvardi的化学、制造和控制副总裁。2015年3月至2021年10月，陈博士担任咨询公司Cheminopti LLC的所有者和总裁，为CMC发展的各个方面提供战略指导和技术领导。从2019年9月到2021年10月，陈博士在商业阶段制药公司SIGA技术公司担任药物开发和制造总监，负责监督美国和欧盟早期开发和商业化的药物物质和药物产品CMC活动。陈博士获得美国田纳西州孟菲斯大学分析化学博士学位和中国天津大学化学工程学士和硕士学位。
- Yixin Joseph Chen was appointed as Vice President, Chemistry, Manufacturing and Controls upon the closing of the Merger. Dr. Chen served as Legacy Tvardi's Vice President, Chemistry, Manufacturing and Controls, from October 2021 to April 2025. From March 2015 to October 2021, Dr. Chen served as the Owner and President of Cheminopti LLC, a consulting firm, where he provided strategic guidance and technical leadership for all aspects of CMC development. From September 2019 to October 2021, Dr. Chen served as the Director of Pharmaceutical Development and Manufacturing at SIGA Technology, Inc., a commercial stage pharmaceutical company, where he oversaw both drug substance and drug product CMC activities for early stage development and commercialization in the United States and European Union. Dr. Chen received a Ph.D. in analytical chemistry from the University of Memphis, Tennessee and B.S. and M.S degrees in Chemical Engineering from Tianjin University, China.